Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine - PubMed
4 hours ago
- #COVID-19 vaccine
- #neutralizing antibodies
- #immune correlates
- The study analyzes immune correlates in the NextCOVE trial for the mRNA-1283 COVID-19 vaccine, comparing it with mRNA-1273.
- Higher Day 29 neutralizing antibody (nAb) levels were linked to lower COVID-19 risk and higher relative vaccine efficacy across ancestral D614G, BA.4/BA.5, and XBB.1.5 variants.
- The strongest associations were for XBB.1.5 and BA.4/BA.5 variants, with hazard ratios of 0.41 and 0.49 per 10-fold nAb increase, indicating nAbs remain valid correlates of protection against contemporary strains.